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Summary
A checkpoint surveying the entry into mitosis responds to defects in spindle microtubule assembly/stability. This has been
used to trigger apoptosis in cancer cells, but how the spindle checkpoint couples to the cell survival machinery has
remained elusive. Here, we report that microtubule stabilization engenders a survival pathway that depends on elevated
activity of p34cdc2 kinase and increased expression of the apoptosis inhibitor and mitotic regulator, survivin. Pharmacologic,
genetic, or molecular ablation of p34cdc2 kinase after microtubule stabilization resulted in massive apoptosis independent
of p53, suppression of tumor growth, and indefinite survival without toxicity in mice. By ablating this survival checkpoint,
inhibitors of p34cdc2 kinase could safely improve the efficacy of microtubule-stabilizing agents used to treat common
cancers.
Introduction Thr34→Ala prevented phosphorylation of endogenous survivin,
resulted in apoptosis of various cancer cell types (O’Connor et
Checkpoints act as surveillance mechanisms to ensure proper al., 2000), and suppressed tumor growth in vivo (Grossman et
timing of the cell division cycle (Sherr, 1996). At mitosis, the al., 2001b; Mesri et al., 2001), suggesting that this phosphoryla-
assembly of a bipolar spindle is vital to the preservation of tion step may provide a suitable target for anticancer therapy.
genetic fidelity between daughter cells, and is monitored by a Although the role of p34cdc2-cyclin B1 as a universal mitotic
checkpoint (Rudner and Murray, 1996) that senses microtubule switch is well established (Pines, 1999), its potential contribution
defects (Andersen, 2000) or aberrant kinetochore attachment to cell death/survival during spindle checkpoint activation has
(Nicklas, 1997). Activation of the spindle checkpoint by mitotic remained controversial (Ongkeko et al., 1995; Shi et al., 1994).
stresses causes a prolonged arrest of cell division that may Here we report that elevated p34cdc2 kinase activity during
eventually lead to apoptosis or programmed cell death (Hengart- spindle checkpoint activation results in increased survivin ex-
ner, 2000). This strategy has been exploited for anticancer ther- pression and cancer cell viability. Conversely, sequential abla-
apy, and agents that perturb microtubule dynamics or interfere tion of p34cdc2 kinase activity in mitotically arrested cells removed
with microtubule assembly (Sorger et al., 1997) have shown this survival mechanism, caused massive apoptosis, and dra-
efficacy in the management of common human tumors (Rowin- matically enhanced the anticancer activity of a common micro-
sky and Donehower, 1995).
tubule poison, i.e., taxol, in vivo.
Among the regulators of apoptosis that may affect the cell
death/viability balance of dividing cells, interest has recently
Resultsfocused on the Inhibitor of Apoptosis (IAP) (Deveraux and Reed,
1999) protein and mitotic regulator, survivin (Altieri, 2001). Ex-
Regulation of survivin expression during spindlepressed during cell division in a cell cycle-dependent manner
checkpoint activationand localized to various components of the mitotic apparatus,
Treatment of cervical carcinoma HeLa cells with increasing con-survivin has been implicated in both regulation of spindle micro-
centrations of microtubule modifiers taxol or vincristine resultedtubule function and preservation of cell viability (Altieri, 2001;
in dose-dependent and uniform cell cycle arrest with G2/M DNAReed and Bischoff, 2000). A critical requisite for survivin function
content, as visualized by propidium iodide staining and flowwas identified in the phosphorylation on Thr34 (O’Connor
cytometry (Figure 1A). Spindle checkpoint activation by microtu-et al., 2000) by the main mitotic kinase, p34cdc2-cyclin B1 (Pines,
1999). Accordingly, expression of nonphosphorylatable survivin bule poisons was also associated with a 2- to 5-fold increase
S I G N I F I C A N C E
Protein kinase inhibitors are currently explored as anticancer drugs for their ability to disrupt signaling pathways controlling cell
proliferation and cell survival. However, concerns of specificity, influence of cellular context, and an incomplete understanding of
molecular targets have limited the use of kinase antagonists in cancer therapy. Here, we show that suppression of p34cdc2 kinase in
tumor cells treated with taxol eliminates a critical survival pathway. This results in escape from taxol-imposed mitotic block, massive
apoptosis, and sustained inhibition of tumor growth in vivo. Taxanes are first-line treatment for common human tumors, and the
sequential combination with an antagonist of p34cdc2 kinase may rationally enhance their therapeutic efficacy.
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Figure 1. Effect of spindle checkpoint activation
on survivin expression
A: Cell cycle analysis. HeLa cells were treated
with the indicated increasing concentrations of
taxol (left panel) or vincristine (right panel), har-
vested after 48 hr, and analyzed for DNA content
by propidium iodide staining and flow cytometry.
B: HeLa cells treated with the indicated concen-
trations of taxol or vincristine were harvested
after 48 hr incubation and analyzed for expres-
sion of survivin or -actin by Western blotting.
Numbers indicate fold increase by densitometry
normalized to -actin levels.
C: Northern hybridization. HeLa cells treated with
0.2 M taxol or 50 J/m2 UVB were harvested at
the indicated time intervals (0–12 hr) and total
RNA was hybridized with a -32P-dCTP-labeled
survivin probe followed by autoradiography. The
position of ribosomal RNA bands in ethidium bro-
mide-stained gels is shown.
D: Promoter activity. HeLa cells transfected with
a minimal survivin promoter construct (pLuc-
1430) upstream of a luciferase reporter gene,
were treated with vehicle (None), taxol (2 M),
or UVB (50 J/m2 ) and harvested at the indicated
time intervals, and luciferase activity was deter-
mined in a luminometer. Values were normalized
to -galactosidase expression.
in survivin expression in HeLa cells, as visualized by Western increased survivin expression during spindle checkpoint activa-
tion was investigated. To target p34cdc2 kinase, we first used ablotting (Figure 1B). To determine whether taxol increased sur-
vivin levels via de novo gene expression, Northern hybridization pharmacologic approach with a panel of cyclin-dependent ki-
nase (CDK) inhibitors (Sausville, 2002). Taxol treatment of HeLaexperiments were carried out. Treatment of HeLa cells with taxol
did not result in significant changes in survivin RNA levels (Figure cells resulted in mitotic arrest with elevated p34cdc2 kinase activ-
ity, which remained sustained for a 32 hr culture, as determined1C). In contrast, DNA damage-induced G2/M arrest by exposure
to 50 J/m2 UVB was associated with loss of endogenous survivin by MPM-2 phosphoepitope expression (Vandre and Borisy,
1989) (Figure 2A). Sequential addition of the 2,6,9 trisubstituteRNA expression, as visualized by Northern blotting (Figure 1C).
Next, we transfected HeLa cells with a minimal survivin promoter purine analog of the CDK ATP binding site, Purvalanol A (Purv.A)
(Gray et al., 1998), to taxol-treated cells suppressed MPM-2upstream of a luciferase reporter gene. In untreated cultures,
there was a time-dependent increase in luciferase activity di- expression at the earliest time point tested (16 hr), and through-
out a 32 hr culture (Figure 2A). In contrast, MPM-2 detectionrected by the minimal survivin promoter, in agreement with
previous observations (Li et al., 1998). In contrast, taxol or UVB was partially inhibited by CDK inhibitors alsterpaullone, flavopi-
ridol, or olomoucine by 16 hr, and completely suppressed bytreatments significantly inhibited survivin promoter activity at all
time intervals tested (Figure 1D). 32 hr (Figure 2A). When analyzed for DNA content, sequential
addition of Purv.A or the other CDK inhibitors to taxol-treated
HeLa cells resulted in escape from the mitotic block and promi-Effect of targeting p34cdc2 kinase activity on cell cycle
progression and apoptosis nent appearance of apoptosis (Figure 2B, see below). For high
affinity and improved specificity for p34cdc2 as compared to otherMitotic arrest induced by spindle poisons is typically associated
with elevated p34cdc2 kinase activity due to persistence of cyclin CDKs (Gray et al., 1998), we used Purv.A in subsequent experi-
ments of pharmacologic inhibition of p34cdc2 kinase. To furtherB1 (Hagtig et al., 1998). The possibility that phosphorylation
on Thr34 by p34cdc2 (O’Connor et al., 2000) may contribute to investigate the ability of Purv.A to suppress p34cdc2 activity in
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vivo, the p34cdc2-cyclin B1 complex was immunoprecipitated
from taxol-treated cultures in the presence or absence of Purv.A
and analyzed for phosphorylation of histone H1 in a kinase
assay. Taxol treatment resulted in increased H1 phosphorylation
by p34cdc2-cyclin B1, as compared with control cultures (Figure
2C). In contrast, sequential addition of Purv.A after taxol treat-
ment suppressed p34cdc2 phosphorylation of H1 to background
levels of untreated cells (Figure 2C).
Requirement of p34cdc2 phosphorylation
for survivin stability
Next, we asked if inhibition of p34cdc2 kinase by Purv.A affected
mitotic phosphorylation of survivin on Thr34. Although high con-
centrations of Purv.A may conceivably affect Cdk2 kinase activ-
ity (Gray et al., 1998), this is inconsequential for survivin function,
as recombinant Cdk-2-cyclin E did not phosphorylate survivin
on Thr34 or other residues in a kinase assay, and did not associ-
ate with survivin, as visualized by coimmunoprecipitation
(O’Connor et al., 2000). Sequential addition of Purv.A to taxol-
treated HeLa cells suppressed survivin phosphorylation on Thr34
(O’Connor et al., 2000), as visualized by Western blotting of
survivin immunoprecipitates with a Thr34-phospho-specific anti-
body (Figure 3A). Loss of survivin phosphorylation on Thr34 was
also associated with inhibition of increased survivin expression
after taxol treatment, as visualized by Western blotting (Figure
3B). In contrast, Purv.A alone, or the reverse sequence of Purv.A
followed by taxol, did not affect survivin levels in HeLa cells
(Figure 3B). Because increase in survivin expression after spin-
dle checkpoint activation did not involve changes in RNA levels
or promoter activity, we asked whether Thr34 phosphorylation
by p34cdc2 influenced survivin stability. The half-life (t1/2) of endog-
enous survivin has been determined in recent studies (Zhao et
al., 2000). To ascertain a role of Thr34 phosphorylation in this
process, HeLa cells were transfected with HA-tagged wild-type
survivin or nonphosphorylatable HA-survivin(T34A), metaboli-
cally labeled with 35S-methionine and 35S-cysteine for 5 hr,
chased with complete medium, and sequentially immunoprecip-
itated with an antibody to HA. In these experiments, 35S-labeled
wild-type survivin was progressively reduced over time with an
estimated t1/2 of 240 min (Figure 3C). In contrast, 35S-labeled
survivin(T34A) exhibited significantly accelerated clearance,Figure 2. Effect of CDK inhibitors on cell cycle progression and kinase activity
with an apparent t1/2 of 90 min (Figure 3C).A: MPM-2 mitotic phosphoepitope expression. HeLa cells were treated with
taxol (0.2 M for 16 hr, black bars) followed by CDK inhibitors Purvalanol A We next used a genetic approach to probe the role of p34cdc2
(Purv.A, 10 M), alsterpaullone (Alster., 20 M), flavopiridol (Flavop., 250 kinase on survivin expression. For these experiments, we took
nM), or olomoucine (Olom., 400 M) for additional 16 hr (gray bars) or 32
advantage of HT2-19 cells carrying an inactivated allele ofhr (striped bars). Cells were harvested and analyzed for MPM-2 mitotic
p34cdc2 and a second allele that is conditionally silenced uponphosphoepitope expression by flow cytometry. Data are expressed as % of
MPM-2 cells in the entire cell population analyzed by propidium iodide removal of IPTG (Itzhaki et al., 1997). In the presence of IPTG
staining. (p34cdc2 /), HT2-19 cells expressed p34cdc2 and endogenous
B: DNA content analysis. HeLa cells were treated with 0.2 M taxol for 16
survivin, as visualized by Western blotting (Figure 3D). A 48 hrhr followed by the various CDK inhibitors as described in A. Cells were
culture in the absence of IPTG (p34cdc2 /) resulted in nearlyharvested after an additional 16 hr culture and analyzed for DNA content
by propidium iodide staining and flow cytometry. The percentage of hypo- complete loss of both p34cdc2 and survivin expression (Figure
diploid cells with sub-G1 (apoptotic) DNA content is indicated. 3D), consistent with the requirement of p34cdc2 kinase activity in
C: Kinase assay. Cyclin B1 was immunoprecipitated from HeLa cells treated
survivin stability. Taxol treatment resulted in increased survivinwith vehicle (None), taxol (0.2 M for 16 hr), Purv.A (10 M for 16 hr), or the
indicated combinations as described in A. The immune complexes were levels in IPTG HT2-19 cells, whereas only a minimally detect-
incubated with histone H1 in a kinase buffer containing -32P ATP for 30 min able survivin band was observed in the absence of IPTG (Figure
at 30C before analysis by autoradiography (top panel). Samples were 3D). This may reflect a residual population of mitotic cells exhib-
analyzed by Western blotting with an antibody to cyclin B1 to confirm
iting p34cdc2 kinase activity, as determined by the presence ofcomparable immunoprecipitation of the CDK1 complex under the various
conditions tested (bottom panel). detectable MPM-2-expressing HT2-19 cells after taxol treat-
ment (Figure 3D).
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Figure 3. Requirement of Thr34 phosphorylation
by p34cdc2 for survivin stability
A: Inhibition of survivin phosphorylation on Thr34
by Purv.A. HeLa cells were incubated with vehi-
cle (None), taxol (0.2M for 16 hr), or the sequen-
tial combination of taxol (0.2 M for 16 hr) fol-
lowed by Purv.A (20 M for 16 hr). Cells were
immunoprecipitated with an antibody to survivin
and the immune complexes were analyzed by
Western blotting with a T34-phospho-specific an-
tibody (Survivin-T34*) or an antibody to survivin
(Survivin).
B: Effect of Purv.A on survivin expression. HeLa
cells were left untreated (None) or treated with
taxol (0.2 M), taxol (0.2 M for 16 hr) followed
by Purv.A (20M for 16 hr), or in reverse combina-
tion, and analyzed for expression of survivin or
cyclin B1 by Western blotting.
C: Regulation of survivin turnover by Thr34 phos-
phorylation. HeLa cells were transfected with HA-
survivin or HA-survivin(T34A) by lipofectamine,
metabolically labeled with 300 Ci/ml of 35S-
methionine/35S-cysteine in methionine- and cys-
teine-free medium for 5 hr, chased with com-
plete medium, and immunoprecipitated at the
indicated time intervals with an antibody to HA.
Bands were revealed by autoradiography and
quantified by densitometry.
D: Conditional ablation of p34cdc2 gene expres-
sion. HT2-19 cells in the presence (p34cdc2 /) or
absence (p34cdc2 /) of IPTG for 24 hr were
treated with vehicle or taxol (0.2 M) for addi-
tional 24 hr, and analyzed for expression of
p34cdc2 or survivin by Western blotting. *, nonspe-
cific band. The percentage of MPM-2 cells in
the presence or absence of taxol is indicated.
Sequential ablation of p34cdc2 kinase activity throughout a 32 hr culture (Figure 4C). Similarly, substituting
Purv.A with the DNA damaging agent, adriamycin (100 nM), orafter spindle checkpoint activation
induces massive apoptosis the nucleoside analog 5-fluorouracile (5-FU, 500 M) after taxol
treatment did not result in enhanced apoptosis, as comparedTreatment of HeLa cells with 0.2 M taxol resulted in homoge-
neous mitotic arrest, negligible apoptosis for up to 32 hr (see with single agent treatment (Figure 4C, inset). Lastly, induction of
apoptosis by taxol-Purv.A was observed in prostate carcinomabelow), and maximal MPM-2 phosphoepitope expression (Fig-
PC3 cells carrying mutated p53, whereas taxol or Purv.A alone,ure 4A). Incubation with Purv.A alone also resulted in uniform
or the reverse combination of Purv.A-taxol, was ineffective (Fig-mitotic arrest with loss of MPM-2 expression, and undetectable
ure 4D). Consistent with the role of p34cdc2 phosphorylation inlevels of apoptosis (Figure 4A). In contrast, sequential addition
survivin stability, taxol treatment caused increased survivin ex-of Purv.A to taxol-arrested HeLa cells resulted in escape from
pression in PC3 cells, in a reaction reversed by sequential addi-the mitotic block and appearance of a large population with
tion of Purv.A, as visualized by Western blotting (Figure 4D,hypodiploid, i.e., apoptotic, DNA content, by propidium iodide
inset).staining and flow cytometry (Figure 4A). Purv.A induction of
apoptosis after taxol treatment was concentration- and time-
dependent. Maximal induction of cell death was observed after Requirement for p34cdc2 kinase
in survivin cytoprotectiona 16 hr treatment of HeLa cells with taxol (0.2 M) followed by
an additional 16 hr exposure to 10–20 M Purv.A (Figure 4B). We next used a molecular approach to target p34cdc2 kinase
activity during spindle checkpoint activation. For these experi-At this time interval,80% of the HeLa cell population exhibited
hypodiploid (apoptotic) DNA content, as opposed to 16% or ments, we transfected HeLa cells with a kinase-dead p34cdc2
(D146N) dominant negative mutant (van den Heuvel and Harlow,7% cell death in cultures treated with taxol or Purv.A alone,
respectively (Figure 4A). Similar results were obtained with 1993), which was previously characterized for suppression of
survivin phosphorylation on Thr34, in vivo (O’Connor et al., 2000)breast carcinoma MCF-7 cells carrying wild-type p53 (not
shown). Induction of apoptosis by the taxol-Purv.A sequential Transfection of HeLa cells with p34cdc2 (D146N) resulted in prom-
inent expression of p34cdc2-reactive material, as visualized bycombination was also strictly sequence-dependent and drug-
specific. Treatment of HeLa cells with the reverse combination Western blotting (Figure 7A, inset), with negligible apoptosis
by DNA content analysis (Figure 5A), and in agreement withof Purv.A for 16 hr followed by taxol (0.2 M) for an additional
16 hr resulted in a sustained mitotic arrest with undetectable published data (van den Heuvel and Harlow, 1993). In contrast,
expression of p34cdc2 (D146N) in taxol-treated HeLa cells re-MPM-2 expression (not shown), but negligible apoptosis
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Figure 4. Induction of apoptosis by sequential ablation of p34cdc2 kinase after spindle checkpoint activation
A: DNA content analysis and kinase activity. HeLa cells were treated with taxol (0.2 M for 16 hr), Purv.A (10 M for 16 hr), or the sequential combination
of taxol (0.2 M for 16 hr) followed by Purv.A (10 M for additional 16 hr), and analyzed for MPM-2 expression (top panel, MPM-2) or DNA content by
propidium iodide staining and flow cytometry (bottom panel, PI). A box contains the MPM-2 cell population under the various conditions tested. The
percentage of hypodiploid cells with sub-G1 DNA content is indicated.
B: Time course of apoptosis and concentration dependence. HeLa cells incubated with 0.2 M taxol for 16 hr (white bars) were sequentially treated with
1 M (striped bars), 10 M (black bars) or 20 M (gray bars) Purv.A. Cells were harvested at the indicated time intervals and analyzed for hypodiploid
(apoptotic) DNA content by propidium iodide staining and flow cytometry.
C: Sequence specificity. HeLa cells treated with Purv.A (20 M, gray bars), Purv.A-taxol (0.2 M) in reverse combination (striped bars), or taxol-Purv.A (black
bars) were analyzed for induction of apoptosis as in B. Inset: Drug specificity. HeLa cells were treated with taxol (0.2 M) or the sequential combination of
taxol-Purv.A (Purv.A, 10 M), taxol-adriamycin (Adria, 100 nM), or taxol-5-Fluorouracil (5-FU, 500 M) and analyzed for induction of apoptosis as in B.
D: p53 independence. Prostate carcinoma PC3 cells were treated with the indicated combinations, harvested after 16 hr, and analyzed for induction of
apoptosis as in B. Inset: Modulation of survivin expression. PC3 cells were left untreated (None) or incubated with the various indicated combinations, and
analyzed for expression of survivin or p53 by Western blotting.
sulted in massive induction of apoptosis as compared with al., 1997). Under these experimental conditions, and in agree-
ment with the data of pharmacologic (Purv.A) or molecularcontrol cultures transfected with pcDNA3 vector (Figure 5A).
Finally, we investigated a potential modulation of taxol- (p34cdc2 DN expression) interference with p34cdc2 activity, taxol
treatment of IPTG HT2-19 cells (p34cdc2 /) resulted in escapeinduced apoptosis in p34cdc2 conditional knockout cells. In the
presence of a functional p34cdc2 allele (p34cdc2 /), HT2-19 cells from the mitotic block, and significantly increased apoptosis,
as compared with untreated IPTG cultures (Figure 5B). Uponexhibited negligible apoptosis, and responded to taxol with ho-
mogeneous mitotic arrest (Figure 5B). Upon IPTG withdrawal, prolonged exposure to taxol-Purv.A (72–96 hr), a fraction of
HT2-19 cells with 8N and 16N DNA content was also observedp34cdc2 / HT2-19 cells also exhibited mitotic arrest and a mod-
est increase in the fraction with hypodiploid (apoptotic) DNA (not shown), suggestive of DNA endoreduplication and poly-
ploidy (Itzhaki et al., 1997). To determine if expression of survivincontent, in agreement with published observations (Itzhaki et
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was sufficient to rescue p34cdc2 / cells from apoptosis, we used
replication-deficient adenoviruses encoding wild-type survivin
(pAd-Survivin) or a reporter marker (pAd-GFP) characterized in
previous studies (Mesri et al., 2001). Infection of HT2-19 cells
with pAd-Survivin or pAd-GFP resulted in comparable levels of
GFP expression in 95% of the transduced cell population, as
visualized by fluorescence microscopy (not shown). Consistent
with the data presented above, loss of p34cdc2 resulted in time-
dependent induction of apoptosis in IPTG HT2-19 cells (Itzhaki
et al., 1997), which was not affected by infection with pAd-
GFP (Figure 5C). In contrast, adenoviral expression of survivin
suppressed apoptosis in p34cdc2 / cells to background levels
of untreated, IPTG cultures (Figure 5C).
Taxol-Purv.A treatment activates mitochondrial-
dependent apoptosis
To identify the apoptotic pathway induced by loss of survivin
phosphorylation on Thr34 during spindle checkpoint activation,
we first looked at the profile of caspase activation under these
experimental conditions. Exposure of HeLa cells to taxol-Purv.A
sequential treatment was associated with proteolytic pro-
cessing of the46 kDa mitochondrial initiator caspase-9 (Wang,
2001) to a 37 kDa active fragment (Figure 6A). In contrast,
treatment with Purv.A or taxol alone did not result in significant
caspase-9 cleavage (Figure 6A). Next, we used cell lines geneti-
cally deficient in selected apoptosome proteins. Treatment of
wild-type mouse embryonic fibroblasts (MEFs) expressing en-
dogenous survivin (not shown) with the sequential combination
of taxol-Purv.A resulted in induction of apoptosis, whereas sin-
gle agent treatment was ineffective (Figure 6B). In striking con-
trast, apoptosis induced by taxol-Purv.A was completely ab-
lated in MEFs deficient in caspase-9 (Hakem et al., 1998) or
Apaf-1 (Yoshida et al., 1998) (Figure 6B), the critical components
of the apoptosome in mitochondrial-mediated apoptosis (Wang,
2001).
p34cdc2 cytoprotection by survivin requires
a stabilized microtubule environment
To determine a potential role of microtubule integrity in p34cdc2/
survivin cytoprotection, we used the microtubule-depolymeriz-
ing agent, vincristine. Treatment of HeLa cells with vincristine
resulted in a sustained mitotic (prometaphase) arrest with ele-
vated p34cdc2 kinase activity (Figure 7A), and increased survivin
expression, as visualized by Western blotting (Figure 1B). Se-
quential addition of Purv.A to vincristine-treated cells sup-
pressed p34cdc2 kinase activity at the earliest time point testedFigure 5. Requirement of p34cdc2 for metaphase viability checkpoint
of 8 hr, by loss of MPM-2 mitotic phosphoepitope expressionA: Molecular targeting of p34cdc2 kinase. HeLa cells were transfected with
pcDNA3 (vector) or kinase-dead p34cdc2 (D146N) dominant negative mu- (Figure 7A). Similar results were obtained in a kinase assay, in
tant (Cdc2DN) in the presence or absence of taxol (0.2 M), and analyzed which p34cdc2 immunoprecipitated from vincristine-treated cells
for DNA content by propidium iodide staining and flow cytometry. The phosphorylated histone H1 in a reaction entirely suppressed by
percentage of cells with hypodiploid (apoptotic) DNA content is indicated
treatment with Purv.A in vivo (Figure 7B). However, at strikingper each condition tested. Inset: Expression of p34cdc2. Control HeLa cells
variance with taxol, sequential addition of Purv.A to vincristine-or cultures transfected with kinase-dead dominant negative p34cdc2
(Cdc2DN) in the presence or absence of taxol were analyzed with an treated cells did not result in induction of apoptosis, which
antibody to p34cdc2 by Western blotting. remained unchanged at background levels throughout a 32 hr
B: Genetic ablation of p34cdc2. HT2-19 cells in the presence (p34cdc2 /) or
culture (Figure 7C), irrespective of loss of survivin expression,absence (p34cdc2 /) of IPTG were simultaneously treated with vehicle or
taxol (0.2M for 24 hr) and analyzed for induction of apoptosis by propidium
iodide staining and flow cytometry. The percentage of cells with hypodip-
loid (apoptotic), 2N, or 4N DNA content is indicated.
C: Expression of survivin reverses apoptosis induced by ablation of p34cdc2.
HT2-19 cells in the absence of IPTG (p34cdc2 /) were infected with pAd- and flow cytometry. The percentage of apoptosis in IPTG HT2-19 cells in
GFP (black bars) or pAd-Survivin (white bars) and analyzed for induction the absence of viral transduction was 17.4% (48 hr) and 24% (72 hr). For
of apoptosis at the indicated time intervals by propidium iodide staining both panels, data are representative of two independent determinations.
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by 21–23 days (Figures 8A–8C). In contrast, sequential adminis-
tration of taxol followed by Purv.A suppressed tumor growth in
a concentration-dependent manner (Figure 8A). Consistent with
the data of sequence specificity in vitro (Figure 4C), the reverse
combination of Purv.A followed by taxol did not reduce tumor
growth, and actually enhanced tumor expansion (not shown).
In survival curves, the taxol-Purv.A sequential treatment resulted
in significantly improved animal survival even after suspension
of treatment, as compared with single-agent therapy alone (Fig-
ure 8B; p	 0.0008 for 5 mg/kg taxol). In addition, the continued
administration of taxol-Purv.A sequential treatment resulted in
indefinite survival of all animals (Figure 8B). To determine if
tumors retained sensitivity to the taxol-Purv.A sequential regi-
men, animals were given one taxol-Purv.A cycle, followed by a
6 day interruption before readministration of treatment. In these
animals, MCF-7 tumors doubled in size during the suspension of
treatment (Figure 8C). However, reintroduction of taxol-Purv.A
sequential therapy suppressed additional tumor growth and af-
forded long-term survival of all treated animals (Figure 8C). None
of the animals in the various treatment groups exhibited signs
of systemic toxicity throughout the different treatment cycles.
Discussion
In this study, we have shown that survival signals emanating
from the mitotic apparatus can preserve the viability of cancer
cells in response to microtubule poisons (Sorger et al., 1997).
Critical requirements of this pathway included elevated levels
of p34cdc2 kinase activity, which in turn promoted increased
expression of the apoptosis inhibitor and mitotic regulator, sur-
vivin (Altieri, 2001), and the presence of stabilized microtubules
Figure 6. Suppression of p34cdc2 kinase after spindle checkpoint activation (Yvon et al., 1999). Conversely, pharmacologic, genetic or mo-
induces mitochondrial-dependent apoptosis lecular ablation of p34cdc2 kinase in mitotically arrested cells
A: Caspase-9 cleavage. HeLa cells were left untreated (None) or treated resulted in escape from the mitotic block, loss of survivin expres-
with taxol (0.2 M), Purv.A (20 M), or the sequential combination taxol- sion, massive activation of mitochondrial-mediated apoptosisPurv.A for 16 hr, and analyzed for caspase-9 cleavage by Western blotting.
independent of p53, and strong antitumor efficacy without toxic-Arrows indicate the position of 46 kDa proform and 37 kDa active form
of caspase-9, respectively. *, nonspecific band. ity, in vivo.
B: Analysis of apoptosome-deficient MEFs. Wild-type MEFs or MEFs isolated A potential role of CDK activity, and p34cdc2 in particular, in
from caspase-9 or Apaf-1 knockout mice were incubated with vehicle apoptosis has been extensively debated. Although unscheduled
(none), taxol (0.2 M for 16 hr), Purv.A (20 M for 16 hr), or taxol-Purv.A in
CDK activity has been associated with cell death (Shi et al.,sequential combination. Cells were harvested and analyzed for DNA con-
1994; Wang and Walsh, 1996) and caspase activation (Harveytent by propidium iodide staining and flow cytometry. The percentage of
hypodiploid cells is indicated. Data are from a representative experiment et al., 2000), the significance of elevated CDK activity during
of at least two independent determinations. spindle checkpoint activation, and its potential participation in
apoptosis, has remained uncertain. In fact, recent genetic evi-
dence suggests that endogenous inhibitors of p34cdc2 kinase
may trigger apoptosis and function as tumor suppressors. Ac-
as visualized by Western blotting (Figure 7C, inset). After a cordingly, disruption of the human homolog of the Drosophila
prolonged 96 hr culture, vincristine induced a comparable level lats gene resulted in deregulated p34cdc2 kinase activity, in-
of apoptosis in HeLa cells with or without Purv.A (not shown). creased cell proliferation, and tumor formation (Tao et al., 1999).
In addition, loss of heterozygosity of the human LATS1 locus
Sequential taxol-Purv.A treatment as a novel has been demonstrated in human tumors (Theile et al., 1996),
anticancer regimen and forced expression of human LATS1 suppressed p34cdc2
To investigate the potential efficacy of taxol-purv.A sequential kinase activity and caused mitotic arrest and apoptosis (Xia et
treatment in vivo, we used a breast cancer xenograft model al., 2002). A role of p34cdc2 kinase activity in preserving cell
extensively characterized in recent studies of survivin targeting viability was also suggested by conditional knockout studies,
(Mesri et al., 2001). Subcutaneous injection of MCF-7 cells in in which deletion of both p34cdc2 alleles caused apoptosis and
immunocompromised CB-17 SCID mice gave rise to exponen- DNA endoreduplication (Itzhaki et al., 1997).
tially growing tumors (Figure 8A), in agreement with previous In agreement with earlier predictions (Ongkeko et al., 1995),
observations (Mesri et al., 2001). Treatment with vehicle, taxol the data presented here are consistent with a model of p34cdc2-
alone (2.5 or 5 mg/kg), or Purv.A alone (20 mg/kg) did not affect dependent cytoprotection at mitosis using survivin (Altieri, 2001)
as one of the critical downstream effector genes. This fits wellthe kinetics of tumor growth, and resulted in loss of all animals
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with the cell cycle-dependent expression of survivin at mitosis
(Li et al., 1998), its physical association with p34cdc2, and the
phosphorylation on Thr34 by p34cdc2-cyclin B1 as a requirement
for survivin cytoprotection (O’Connor et al., 2000). A preferential
survivin-cyclin B1 relationship was independently recognized in
recent gene profiling studies of large cell non-Hodgkin’s lym-
phoma, and correlated with a more aggressive disease pheno-
type (Kuttler et al., 2002). As shown here, one of the mechanisms
by which p34cdc2 phosphorylation may regulate survivin is by
promoting its increased stability at mitosis. This may cooperate
with the cell cycle periodicity of survivin gene transcription at
G2/M (Li et al., 1998) to achieve maximal levels of survivin
expression at cell division. Phosphorylation of cell death regula-
tors has been previously implicated in modulation of protein
stability, and phosphorylation of Bcl-2 on MAP kinase sites
Thr56, Thr74, and Ser87 (Breitschopf et al., 2000), or p53 on Ser15
and Ser20 (Hirao et al., 2000), counteracts ubiquitin-dependent
protein degradation. Proteasome-dependent destruction plays
a critical role in regulating the expression of IAP family proteins
(Yang et al., 2000), including survivin (Zhao et al., 2000), and
may contribute, at least under certain circumstances, to their
cytoprotective function(s) (Huang et al., 2000). In this context,
interference with survivin phosphorylation on Thr34 by dominant
negative mutant (O’Connor et al., 2000), or by targeting p34cdc2
(this study), is expected to destabilize survivin levels at mitosis
favoring accelerated clearance and induction of apoptosis.
Consistent with this model, loss of survivin expression by
antisense targeting has been invariably associated with sponta-
neous apoptosis (Li et al., 1999), enhancement of chemother-
apy-induced cell death (Olie et al., 2000), and antitumor activity
in vivo (Kanwar et al., 2001). The mechanism(s) by which ele-
vated levels of survivin are required to preserve an antiapoptotic
threshold at mitosis has been debated (Altieri, 2001), and, unlike
other IAP proteins (Deveraux and Reed, 1999), may not involve
direct inhibition of caspase-3 activity (Verdecia et al., 2000).
Here, apoptosis induced by destabilization of survivin in taxol-
Purv.A-treated cells resulted in caspase-9 cleavage, and was
abolished in cells genetically deficient in caspase-9 (Hakem et
al., 1998) or Apaf-1 (Yoshida et al., 1998), the critical compo-
nents of the apoptosome in mitochondrial-mediated cell death
(Wang, 2001). These data are in agreement with recent observa-
tions that dominant negative interference with survivin phos-
phorylation on Thr34 resulted in cytochrome c release and cas-
pase-9 activation (Mesri et al., 2001), and transgenic animals
expressing survivin were protected against UVB- (mitochon-
drial), but not Fas (death receptor)-induced apoptosis (Gross-
man et al., 2001a). The ability of survivin to selectively regulate
mitochondrial apoptosis may also explain the lack of evolution-
ary conservation of this cytoprotective pathway in C. elegans,
where the mitochondria does not participate in cell death (Wang,
Figure 7. Requirement of stabilized microtubules for metaphase viability
checkpoint by Western blotting with an antibody to cyclin B1 to confirm equal immuno-
A: MPM-2 activity. HeLa cells were treated with vincristine (100 nM for 16 precipitation of the CDK1 complex under the various conditions tested
hr, white bars) or vincristine followed by Purv.A (20 M, black bars), and (bottom panel).
analyzed for MPM-2 mitotic phosphoepitope expression at the indicated C: Determination of apoptosis. HeLa cells were treated with vincristine (100
time intervals. nM for 16 hr, white bars) or vincristine followed by Purv.A (20 M, white
B: Kinase assay. HeLa cells treated with vincristine, Purv.A, or the indicated bars), and analyzed for DNA content at the indicated time intervals. Inset:
combinations as described in A were immunoprecipitated with an antibody modulation of survivin expression. HeLa cells left untreated (None) or treated
to cyclin B1 and the immune complexes were mixed with histone H1 and with the various indicated combinations were analyzed for expression of
-32P-ATP followed by autoradiography (top panel). Samples were analyzed survivin or cyclin B1 by Western blotting.
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2001), and a potential survivin homolog, BIR 1, acts exclusively
as a mitotic regulator (Speliotes et al., 2000).
An important requirement of p34cdc2/survivin cytoprotection
was the integrity of microtubules, thus indicating that the cellular
response to spindle checkpoint activation may vary depending
on the status of microtubule dynamics (Sorger et al., 1997).
The fact that loss of survivin resulted in apoptosis only under
conditions of microtubule stabilization may reflect a tightly timed
window of survivin cytoprotection at cell division, which may
coincide with the assembly of a bipolar metaphase spindle. In
this context, survivin cytoprotection has been shown to require
polymerized microtubules (Li et al., 1998), and overexpression
of survivin blocked taxol-induced, but not vincristine-induced,
cell death (Li et al., 1998). This suggests a role of a specialized
“microtubule environment” in p34cdc2/survivin cytoprotection,
potentially recruiting other cell death effectors/regulators, i.e.,
caspase-9 (O’Connor et al., 2000). A microtubule environment
required for survivin cytoprotection is consistent with the pre-
dominant localization of survivin to mitotic spindle microtubules
(Fortugno et al., 2002), anticipated previously (Li et al., 1998),
and its role in microtubule stability (Giodini et al., 2002; Tran et
al., 2002) and spindle checkpoint function (Kallio et al., 2001).
When tested in a xenograft breast cancer model in mice,
sequential ablation of p34cdc2 kinase activity after microtubule
stabilization converted a low-dose, noneffective taxol regimen
into a highly curative treatment that suppressed tumor growth
and afforded indefinite survival of all treated animals. Kinase
inhibitors have recently emerged as promising anticancer
agents (Griffin, 2001), and a flavone CDK inhibitor, flavopiridol,
is currently explored as an anticancer agent (Sausville, 2002).
The concept of sequential therapy provides a rational approach
to improve the efficacy of anticancer regimens, and, consistent
with the data presented here, sequential administration of fla-
vopiridol following taxol treatment enhanced apoptosis in vitro
(Motwani et al., 1999), and is being considered as a therapeutic
regimen for cancer trials (Schwartz et al., 2002). However, fla-
vopiridol functions as a broad inhibitor of various CDKs as well
as non-cell cycle regulated kinases, and its anticancer and pro-
apoptotic properties may be unrelated to p34cdc2 inhibition and
reflect global suppression of gene transcription by targeting theFigure 8. Timed ablation of the metaphase viability checkpoint as a novel
CDK9/cyclin T1 complex (Sausville, 2002). This is consistentantitumor treatment in vivo
with the ability of flavopiridol and the other CDK inhibitors testedA: MCF-7 cells (2.5 
 106 ) were injected subcutaneously in the flank of
here to induce apoptosis even in the absence of other chemo-immunocompromised CB17 SCID mice, and grown as superficial tumors for
5 d (50–75 mm3 ) before initiation of treatment. Animals (6/group) were therapeutic treatments (our unpublished data). In contrast, when
injected i.p. with vehicle, taxol alone (T, 2.5 or 5 mg/kg), or the sequential used alone, the 2,6,9 trisubstitute purine analog Purv.A, pre-
combination of taxol-Purv.A at the indicated intervals (arrows), followed by viously characterized as a more selective inhibitor of p34cdc2a day with no treatment. For single agent treatment, vehicle was given in
(Gray et al., 1998), caused a sustained mitotic block withoutplace of taxol or Purv.A with the same schedule. Each cycle was separated
by 2 days without treatment. Tumor volume was measured in three dimen- accompanied apoptosis. This may contribute to a high degree
sions with a caliper. of specificity of the taxol-Purv.A sequential treatment in vivo,
B: Survival. The experimental conditions are as in A. Treatment was termi- and the latter may explain the lack of systemic toxicity of this
nated on day 16 for all groups except for group, where sequential adminis-
regimen in mice. As shown here, the proapoptotic efficacy oftration of taxol-Purv.A was continued as in A. For all groups, tumor size
taxol-Purv.A was strictly sequence- and drug-dependent, andwas monitored at the indicated time intervals, and animals with tumor
burden 3000 mm3 were sacrificed (Survival). , vehicle; H17009, taxol alone was not observed by substituting Purv.A with a DNA damaging
(2.5 mg/kg); , taxol alone (5 mg/kg); , taxol (2.5 mg/kg)-Purv.A; , taxol agent (adriamycin) or a nucleoside analog (5-FU). Importantly,
(5 mg/kg)-Purv.A; , taxol (2.5 mg/kg)-Purv.A continuous treatment.
the reverse combination of Purv.A followed by taxol not onlyC: Retained sensitivity to treatment. The experimental conditions are as in
failed to promote apoptosis, but also reduced the modest induc-A. In the Purv.A alone group, animals were injected i.p. with 20 mg/kg Purv.A
with the indicated schedule. Sequential treatment with taxol (5 mg/kg) tion of cell death mediated by low-dose taxol, and paradoxically
followed by Purv.A (20 mg/kg) was suspended for the indicated time interval enhanced tumor growth in vivo. This is reminiscent of previous
(Break, 6 days) and readministered on day18 with the same schedule as observations in which inhibition of p34cdc2 kinase by olomoucine
in A. All animals treated with vehicle, taxol alone (5 mg/kg), or Purv.A
(Ye et al., 2001), or via by upregulation of p21Cip1/Waf1 (Yu et al.,alone (20 mg/kg) reached tumor burdens 3000 mm3 on day 20 and were
sacrificed. 1998) actually attenuated apoptosis induced by microtubule
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sciences) in methionine- and cysteine-free medium for 5 hr at 37C, chasedpoisons. One potential explanation that may reconcile previous
in complete medium, and immunoprecipitated with an antibody to HA atdiscrepancies as to the requirement of p34cdc2 in cell death is
increasing time intervals (0–8 hr) after labeling. Radioactive bands werethat premature suppression of p34cdc2 kinase may arrest mitotic
detected by autoradiography and quantified by densitometry.
progression before cells require the enhanced antiapoptotic
environment afforded by p34cdc2/survivin. Pharmacologic, genetic, and molecular targeting
In summary, these data suggest that survival signals engen- of p34cdc2 kinase activity
Pharmacologic suppression of p34cdc2 kinase was carried out with inhibitorsdered by p34cdc2 activity, increased survivin levels, and a stabi-
of cyclin-dependent kinases (CDKs). In a first series of experiments, HeLalized microtubule environment may preserve the viability of can-
cells were incubated with taxol (0.2 M) or vincristine (100 nM) for 16 hr atcer cells during a protracted mitotic arrest. Consistent with the
37C, followed by addition of Purvalanol A (Purv.A, 1–10 M), alsterpaulloneexquisite sensitivity of cancer cells to manipulation of the sur-
(20 M), flavopiridol (250 nM), or olomoucine (400 mM) for increasing time
vivin pathway (Altieri, 2001), timed and sequence-specific abla- intervals (4–32 hr) at 37C. At the end of each time interval, cells were
tion of p34cdc2 kinase after taxol treatment may destabilize sur- harvested and analyzed for p34cdc2 kinase activity and DNA content analysis
vivin levels, remove this survival checkpoint, and promote strong (see below). In all other experiments, HeLa, PC3, or MCF-7 cells or wild-
type MEFs or MEFs isolated from caspase-9- or Apaf-1-deficient mice wereanticancer activity in vitro and in vivo. This may provide a rational
incubated with 0.2 M taxol for 16 hr and sequentially treated with 20 Mapproach to lower the therapeutic concentrations of taxane-
Purv.A for an additional 16 hr before analysis of p34cdc2 kinase activity orbased chemotherapy (Rowinsky and Donehower, 1995) and
DNA content (see below). For sequence- and treatment-specificity, HeLa
improve the treatment of common human cancers. cells were incubated with Purv.A (10–20 M) for 16 hr followed by taxol
(0.2 M) for 16 hr, or treated with taxol (0.2 M for 16 hr) followed by the
Experimental procedures
DNA-damaging agent adriamycin (100 nM, Sigma) or the nucleoside analog
5-fluorouracil (500 M, Sigma) for 8 hr at 37C before DNA content analysis.
Cell cultures and antibodies
To determine the effect of pharmacologic inhibition of p34cdc2 kinase activity
Breast carcinoma MCF-7, prostate carcinoma PC3, and cervical carcinoma
on survivin phosphorylation on Thr34, endogenous survivin was immunopre-
HeLa cells (American Type Culture Collection, Manassas, VA) were main-
cipitated from HeLa cells treated with taxol or the sequential combination
tained in culture according to the supplier’s recommendations. HT2-19 cells
of taxol-Purv.A, as described (O’Connor et al., 2000). The immune complexes
with conditional inactivation of the p34cdc2 gene were described previously
were separated by SDS gel electrophoresis and analyzed by Western blotting
(Itzhaki et al., 1997). In this cell line, removal of IPTG from the culture medium
with an antibody to survivin or an affinity-purified Thr34-phospho-specific
results in inactivation of the second p34cdc2 allele (Itzhaki et al., 1997). Trans-
antibody (-survivinT34*) described previously (O’Connor et al., 2000). Forformed mouse embryonic fibroblasts (MEFs) isolated from caspase-9 (Ha-
genetic ablation of p34cdc2, HT2-19 cells were washed and cultivated in thekem et al., 1998) or Apaf-1 (Yoshida et al., 1998) -deficient mice were
absence of IPTG for 48–72 hr before DNA content analysis (see below) ordescribed previously. A replication-deficient adenovirus encoding wild-type
expression of survivin or p34cdc2 by Western blotting. In some experiments,survivin (pAd-Survivin) or control GFP (pAd-GFP) was generated using the
taxol (0.2 M) was added to HT2-19 cells simultaneously with the withdrawalpAd-Easy system, as described previously (Mesri et al., 2001), and propa-
of IPTG, and cells were processed for DNA content analysis or MPM-2gated in HEK293 cells with purification by CsCl banding. With this protocol,
mitotic phosphoepitope expression after a 48 hr culture at 37C. For molecu-no replication-competent adenovirus particles are generated (Mesri et al.,
lar targeting of p34cdc2, HeLa cells were transfected with control plasmid2001). For viral transduction, HT2-19 cells in the absence of IPTG were
pcDNA3 or a kinase-dead p34cdc2 (D146N) dominant negative mutant (vaninfected with pAd-GFP or pAd-Survivin at multiplicity of infection (m.o.i.) of
den Heuvel and Harlow, 1993) by lipofectamine. Transfected cells were50, and analyzed after a 48–72 hr culture for changes in cell cycle progression
simultaneously treated with taxol (0.2 M) so that maximal expression ofand apoptosis. Antibodies to p34cdc2 or cyclin B1 were obtained from Phar-
p34cdc2 DN (24 hr) would occur in the mitotically arrested cell populationmingen (San Diego, CA) or Santa Cruz (Santa Cruz, CA), respectively, and
following spindle checkpoint activation. Cells under the various conditionsused in previous experiments (O’Connor et al., 2000). Antibodies to -actin or
tested were analyzed for protein expression with an antibody to p34cdc2 bycaspase-9 were obtained from Sigma or Transduction Laboratories (Beverly,
Western blotting, or for DNA content by propidium iodide staining and flowMA), respectively. A rabbit polyclonal antibody to survivin was from NOVUS
cytometry.Biologicals (Littleton, CO), and was characterized in recent studies (Fortugno
et al., 2002). An affinity-purified antibody to Thr34-phosphorylated survivin
Determination of p34cdc2 kinase activity(-survivinT34*) was characterized previously (O’Connor et al., 2000).
For detection of mitotic proteins expressing the MPM-2 phosphoepitope
(Vandre and Borisy, 1989), HeLa cells (1–2 
 105 cells/60 mm dish) wereModulation of survivin expression during checkpoint activation
treated with taxol (0.2 M) or vincristine (100 nM) for increasing time intervalsFor time-course experiments of spindle checkpoint activation, HeLa cells
(8–36 hr) at 37C. Cells were fixed in 70% ethanol and labeled with MPM-2were treated with increasing concentrations of the microtubule-stabilizing
antibody (6 g/ml; Upstate Biotechnology, Lake Placid, NY) followed byagent taxol (2–200 nM, Sigma Chemical Co., St. Louis, MO), or the microtu-
addition of goat anti-mouse FITC (Boehringer Mannheim) for 1 hr at 22Cbule-depolymerizing drug, vincristine (1–100 nM, Sigma) for 48 hr at 37C.
in the presence of 5 g/ml propidium iodide containing 50 g/ml RNase A.Cells were harvested and analyzed for DNA content by propidium iodide
Samples were analyzed on a FACScan (Becton Dickinson, Mountain View,staining and flow cytometry or modulation of survivin expression by Western
CA), using CellQuest software. Data were expressed as % MPM-2 positiveblotting, as described (O’Connor et al., 2000). For Northern hybridization
cells in the entire population. For kinase assays, the p34cdc2-cyclin B1 com-experiments, HeLa cells were exposed to 0.2 M taxol or 50 J/m2 UVB and
plex was immunoprecipitated with an antibody to cyclin B1 (6.6 g/ml) fromharvested at increasing time intervals after treatment (0–12 hr), and total
taxol- or vincristine-treated HeLa cells in the presence or absence of Purv.A.RNA was hybridized with a -32P-dCTP-labeled survivin probe with detection
The immune complexes were mixed with histone H1 as a substrate (1 g)of radioactive bands by autoradiography, as described (Li et al., 1998). In
in kinase buffer containing 20 Ci -32P-ATP for 30 min at 30C, as describedsome experiments, HeLa cells were transfected by lipofectamine with a
(O’Connor et al., 2000), with detection of radioactive bands by autoradiogra-minimal survivin promoter construct upstream of a luciferase reporter gene
phy. Membranes were analyzed for comparable immunoprecipitation of(pLuc-cyc1.2), as described (Li et al., 1998). Cells were treated with taxol
p34cdc2-cyclin B1 by Western blotting with an antibody to cyclin B1.(2 M) or UVB (50 J/m2 ), and analyzed for changes in luciferase activity at
increasing time intervals (12–36 hr) in a luminometer. Luciferase values were
normalized to -galactosidase expression. For analysis of survivin stability, Determination of apoptosis
Changes in apoptosis in cultures treated with the microtubule poisons orHeLa cells were transfected by lipofectamine with HA-tagged wild-type
survivin or nonphosphorylatable survivin(T34A), as described previously CDK inhibitors, alone or in sequential combination, were monitored by DNA
content analysis by propidium iodide staining and flow cytometry, as de-(O’Connor et al., 2000). For pulse-chase experiments, cells were metaboli-
cally labeled with 300 Ci/ml of 35S-methionine/35S-cysteine (Amersham Bio- scribed (Li et al., 1999). In other experiments, HeLa cells were detergent-
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keratinocytes counteracts UVB-induced apoptosis and cooperates with losssolubilized and analyzed for proteolytic processing of 46 kDa proform
of p53. J. Clin. Invest. 108, 991–999.caspase-9, by Western blotting (O’Connor et al., 2000).
Grossman, D., Kim, P.J., Schechner, J.S., and Altieri, D.C. (2001b). Inhibition
Breast cancer xenograft model of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad.
All experiments involving animals were approved by the institutional animal Sci. USA 98, 635–640.
care and use committee. Six- to eight-week-old female CB17 SCID/beige
Hagtig, A., Karlsson, C., Clute, P., Jackman, M., and Pines, J. (1998). MPFmice (Taconic Farms, Germantown, NY) were injected s.c. into the flanks
localization is controlled by nuclear export. EMBO J. 17, 4127–4138.with 2.5 
 106 exponentially growing MCF-7 cells in 250 l of sterile PBS
(pH 7.4). Tumor growth was confined to local masses and did not affect
Hakem, R., Hakem, A., Duncan, G.S., Henderson, J.T., Woo, M., Soengas,
animal survival over a 4 month observation period. Tumors became palpable
M.S., Elia, A., de la Pompa, J.L., Kagi, D., Khoo, W., et al. (1998). Differential
(75 mm3 ) within 5 days of tumor cell injection, after which groups of
requirement for caspase-9 in apoptotic pathways in vivo. Cell 94, 339–352.
six animals were randomized and assigned to different treatment groups.
Animals were injected i.p. with taxol alone (2.5 or 5 mg/kg), Purv.A alone Harvey, K.J., Lukovic, D., and Ucker, D.S. (2000). Caspase-dependent Cdk
activity is a requisite effector of apoptotic death events. J. Cell Biol. 148,(20 mg/kg), or the sequential combination of taxol-Purv.A for two consecutive
59–72.days each divided by a day with no treatment. For single agent treatment,
vehicle was given in place of taxol or Purv.A with the same schedule. Each
Hengartner, M.O. (2000). The biochemistry of apoptosis. Nature 407, 770–
complete cycle was separated by 2 days without treatment. Tumor volume
776.
was measured in the three dimensions with a caliper. Animals with tumor
burden 3000 mm3 were sacrificed (Survival). Hirao, A., Kong, Y.-Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H.,
Liu, D., Elledge, S.J., and Mak, T.W. (2000). DNA damage-induced activation
Statistical analysis of p53 by the checkpoint kinase Chk2. Science 287, 1824–1827.
All in vitro experiments were repeated at least three times. For in vivo studies,
Huang, H., Joazeiro, C.A.P., Bonfoco, E., Kamada, S., Leverson, J.D., andeach X value (time) shows the fraction of animals still alive calculated using
Hunter, T. (2000). The inhibitor of apoptosis, c-IAP2, functions as a ubiquitin-the product limit or Kaplan-Meier method. The survival curves were com-
protein ligase and promotes in vitro monoubiquitination of caspases 3 and
pared using the log-rank test. This test generates a p value testing the null
7. J. Biol. Chem. 275, 26661–26664.
hypothesis that the survival curves are identical in the overall populations.
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